List of Excipients in Branded Drug CLARINEX-D 12 HOUR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	CLARINEX-D 12 HOUR	desloratadine and pseudoephedrine sulfate	0085-1322	ALUMINUM OXIDE
Merck Sharp & Dohme Corp	CLARINEX-D 12 HOUR	desloratadine and pseudoephedrine sulfate	0085-1322	ANHYDROUS CITRIC ACID
Merck Sharp & Dohme Corp	CLARINEX-D 12 HOUR	desloratadine and pseudoephedrine sulfate	0085-1322	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	CLARINEX-D 12 HOUR	desloratadine and pseudoephedrine sulfate	0085-1322	EDETATE DISODIUM
Merck Sharp & Dohme Corp	CLARINEX-D 12 HOUR	desloratadine and pseudoephedrine sulfate	0085-1322	FD&C BLUE NO. 2

CLARINEX-D 12 HOUR Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

CLARINEX-D 12 HOUR combines desloratadine 2.5 mg with pseudoephedrine sulfate 120 mg in an extended-release tablet. Its commercial value is tied less to novel pharmacology than to the formulation challenge of delivering an immediate or rapid antihistamine effect while controlling pseudoephedrine release over approximately 12 hours. The product creates opportunities for generic manufacturers, reformulators, contract manufacturers, and excipient suppliers in extended-release matrix design, coating technology, tablet robustness, and abuse-deterrent or pseudoephedrine-control features.

The principal commercial opportunity is a generic or authorized-generic equivalent with reliable 12-hour pseudoephedrine release, low tablet weight, acceptable dissolution performance, and a manufacturing process that avoids complex intellectual-property claims. The main development risks are formulation non-equivalence, dose dumping, pseudoephedrine regulatory controls, and limited market size relative to more established loratadine-pseudoephedrine products.

What is CLARINEX-D 12 HOUR and how is it formulated?

CLARINEX-D 12 HOUR is an extended-release oral tablet containing:

Component	Amount per tablet	Function
Desloratadine	2.5 mg	H1 antihistamine
Pseudoephedrine sulfate	Equivalent to 120 mg pseudoephedrine	Nasal decongestant
Dosage form	Extended-release tablet	Approximately 12-hour delivery

The product is indicated for relief of symptoms associated with seasonal allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and itching. The product uses a combination of two active ingredients with materially different formulation requirements: desloratadine is administered at a low dose and generally requires rapid availability, while pseudoephedrine must be released over an extended period.

The FDA-approved label identifies excipient classes that support tablet compression, matrix formation, film coating, flow, disintegration, and physical stability. Public labeling identifies ingredients including hypromellose, microcrystalline cellulose, dibasic calcium phosphate, povidone, sodium starch glycolate, colloidal silicon dioxide, talc, titanium dioxide, and other coating or processing materials, depending on the specific presentation and labeling version (U.S. Food and Drug Administration, 2005).

What excipients protect the performance of CLARINEX-D 12 HOUR?

The formulation can be analyzed as a functional excipient system rather than as a simple list of inactive ingredients.

Hypromellose and extended-release control

Hypromellose is the most commercially important excipient in the formulation because it can form a hydrated gel matrix that controls pseudoephedrine diffusion and tablet erosion. Its performance depends on:

• Polymer viscosity grade
• Particle size
• Substitution pattern
• Compression force
• Tablet porosity
• Drug-to-polymer ratio
• Dissolution medium and agitation conditions

A generic manufacturer would need to reproduce the reference product's release profile across multiple dissolution conditions. Matching only a single laboratory dissolution point would create regulatory and commercial risk.

Lower-viscosity hypromellose grades can accelerate release and reduce tablet swelling. Higher-viscosity grades can slow release but may increase tablet size, compression sensitivity, and manufacturing variability. A blended polymer system may offer better control than a single-grade matrix, but it can increase process complexity.

Microcrystalline cellulose and tablet structure

Microcrystalline cellulose provides compressibility and contributes to tablet hardness and mechanical integrity. It can also alter matrix porosity and water penetration. Excessive use may accelerate liquid ingress and drug release, while insufficient use can produce weak tablets, capping, or friability problems.

The material is commercially attractive because it is widely available, supported by extensive regulatory precedent, and compatible with direct compression and wet granulation. Its main limitation is that supplier grade, moisture content, and particle-size distribution can affect dissolution performance.

Dibasic calcium phosphate

Dibasic calcium phosphate can increase tablet density and improve flow and compaction. In an extended-release matrix, a dense inorganic filler can reduce tablet volume and support a robust dosage form.

The excipient may also influence release by changing matrix tortuosity and water penetration. Its relatively low solubility can make it useful where excessive matrix porosity must be avoided. Formulators must control interaction risks with acidic or moisture-sensitive components and assess its effect on blend uniformity.

Povidone and colloidal silicon dioxide

Povidone can operate as a binder in granulation and improve mechanical strength. Colloidal silicon dioxide improves powder flow and may reduce segregation in a low-dose formulation containing only 2.5 mg of desloratadine.

Low-dose desloratadine creates a content-uniformity challenge. The active ingredient represents a small fraction of total tablet weight, so the formulation requires a validated blending strategy, controlled particle size, and appropriate sampling design. Excessive glidant levels can affect dissolution and tablet tensile strength.

Sodium starch glycolate

Sodium starch glycolate is typically used as a superdisintegrant. In a controlled-release tablet, its level and location are important. If incorporated in a manner that produces rapid internal tablet disruption, it can undermine the intended pseudoephedrine release profile. If used at a low level or in a segregated portion of the formulation, it may help balance early hydration and tablet integrity.

Film-coating excipients

Film coating protects the tablet, improves appearance, supports identification, and can reduce moisture exchange. Titanium dioxide, talc, hypromellose-based coating systems, and colorants may be used for this purpose.

A conventional film coat is unlikely to be the primary release-controlling barrier if the extended-release behavior is generated by a hydrophilic matrix. That distinction matters for generic development. A manufacturer can potentially use a different coating system if the finished product meets pharmaceutical equivalence, bioequivalence, stability, and dissolution requirements.

What formulation patents protect CLARINEX-D 12 HOUR?

The strongest formulation-related protection for a product of this type would generally arise from claims covering:

1. The combination of desloratadine and pseudoephedrine in a defined dosage range.
2. Extended-release delivery of pseudoephedrine over a specified period.
3. A bilayer, matrix, coated-particle, or multiparticulate dosage form.
4. Specific dissolution ranges at defined time points.
5. Methods of treating allergic rhinitis with the combination.
6. Manufacturing processes that produce a controlled-release profile.
7. Physical separation of the antihistamine and decongestant components.

The commercial significance of any patent depends on claim scope, expiration, terminal disclaimers, maintenance status, prosecution history, and whether the claims cover the marketed product rather than only a broader development concept.

Patent analysis should distinguish between:

• Orange Book-listed patents that may support a Paragraph IV certification.
• Expired patents that may remain technically relevant but do not block launch.
• Unlisted formulation patents that may create litigation risk but do not necessarily delay FDA approval.
• Method-of-use patents that may be addressed through a section viii carve-out.
• Process or manufacturing patents that may affect supply strategy without blocking an ANDA.

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved small-molecule drug products. A current product-specific assessment should use the latest Orange Book entry for NDA 021605 and related FDA records rather than relying on historical patent summaries (U.S. Food and Drug Administration, 2024).

When does CLARINEX-D 12 HOUR lose exclusivity and what generic entry risks exist?

CLARINEX-D 12 HOUR does not have biologic exclusivity, so biosimilar regulation is not relevant. Generic competition would proceed through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The key entry questions are:

Issue	Commercial effect
Listed patent status	Determines Paragraph IV or section viii strategy
Regulatory exclusivity	May delay ANDA approval even after patent expiry
Bioequivalence	May require pharmacokinetic and comparative dissolution evidence
Extended-release profile	Creates higher development risk than an immediate-release tablet
Pseudoephedrine controls	Adds distribution, recordkeeping, and retail restrictions
Market size	May not support multiple generic entrants
Brand availability	A discontinued or limited brand can reduce reference-product demand

For an extended-release combination product, an ANDA applicant may need to demonstrate that the generic has the same active ingredients, dosage form, strength, route of administration, and conditions of use, while also matching the reference product's release characteristics. The FDA may accept different excipients if they do not affect safety, efficacy, or bioequivalence.

A Paragraph IV challenge would be commercially meaningful only if a listed patent remained enforceable and relevant to the proposed product. If the relevant patents have expired or are not listed, the opportunity shifts from patent litigation to technical execution and market economics.

What FDA regulatory issues affect CLARINEX-D 12 HOUR generics?

Pseudoephedrine is subject to federal controls under the Combat Methamphetamine Epidemic Act of 2005. Retail sales are subject to daily and monthly quantity limits, purchaser identification requirements, sales records, and storage requirements. State requirements can be stricter.

These obligations affect:

• Wholesale distribution
• Pharmacy inventory systems
• Online sales
• Retail placement
• Customer verification
• Forecasting and working capital
• Reverse logistics and theft prevention

A generic manufacturer must also address the FDA's expectations for extended-release products. The formulation should be evaluated for dose dumping under relevant alcohol conditions where applicable, food effects, alcohol interaction, tablet integrity, and robustness after storage.

The label must preserve the combination product's approved dosing and warning framework. Because pseudoephedrine can produce cardiovascular and central nervous system effects, formulation changes that accelerate release can have direct safety implications.

What commercial opportunities exist for excipient suppliers?

The principal opportunity is not a single proprietary excipient. It is a validated excipient platform that improves reproducibility and reduces development time.

High-value excipient opportunities

Higher-performance hypromellose systems

Suppliers can offer controlled particle-size, low-variability hypromellose grades optimized for 12-hour matrix tablets. Technical value is highest where the supplier provides dissolution modeling, compaction data, and scale-up support.

Co-processed compression excipients

Co-processed microcrystalline cellulose, calcium phosphate, and flow aids may reduce segregation and improve tablet uniformity. This is particularly relevant because desloratadine is a low-dose active ingredient.

Direct-compression platforms

A direct-compression system can lower manufacturing cost and reduce solvent or drying requirements. The platform must maintain matrix integrity and release control under high-speed tablet compression.

Abuse-deterrent or tamper-resistant systems

Pseudoephedrine's regulatory profile creates an opportunity for tablets that resist crushing, powdering, or extraction. Any such system would need to preserve bioequivalence and avoid unnecessary manufacturing cost.

Moisture-control technologies

Barrier coatings, low-moisture excipients, and optimized packaging can improve stability. The most practical commercial approach may combine a standard matrix with a high-performance film coat and moisture-resistant blister or bottle packaging.

How does CLARINEX-D 12 HOUR compare with competing decongestant products?

Product category	Antihistamine	Decongestant	Release profile	Competitive position
CLARINEX-D 12 HOUR	Desloratadine	Pseudoephedrine	Extended release	Prescription combination product
Loratadine-pseudoephedrine products	Loratadine	Pseudoephedrine	12- or 24-hour forms	Larger consumer recognition and broader historical availability
Cetirizine-pseudoephedrine products	Cetirizine	Pseudoephedrine	Extended release	Competes on antihistamine preference
Antihistamine alone	Various	None	Immediate or extended	Avoids pseudoephedrine restrictions
Intranasal decongestants	None or combination	Topical agents	Local delivery	Different onset and safety profile

The product's differentiation is based on desloratadine rather than on a unique decongestant mechanism. That creates a weaker consumer moat than a product with a distinctive delivery platform or large over-the-counter franchise.

How strong is the patent and formulation estate for CLARINEX-D 12 HOUR?

The formulation estate is likely strongest where claims are tied to a specific extended-release architecture, dissolution range, or manufacturing process. It is weaker where protection depends only on the broad combination of known active ingredients in a conventional tablet.

A practical strength assessment should score the estate across five dimensions:

Dimension	Assessment criteria
Claim breadth	Covers composition, dosage form, release profile, or only a narrow example
Product mapping	Direct correspondence between claims and marketed tablet
Remaining term	Years to expiration and terminal disclaimer effects
Design-around difficulty	Availability of alternate polymers, coatings, or tablet architectures
Litigation leverage	Orange Book listing, infringement evidence, and damages exposure

For a generic entrant, the most realistic design-around paths include changing the matrix polymer grade, using a multilayer tablet, separating immediate-release desloratadine from extended-release pseudoephedrine, or using coated granules within a compressed dosage form. Each design-around must still meet bioequivalence and dissolution requirements.

What licensing and manufacturing opportunities are available?

Licensing opportunities may arise around:

• Extended-release polymer systems
• Coated pseudoephedrine particles
• Low-dose content-uniformity technologies
• Direct-compression manufacturing
• Moisture-resistant packaging
• Tamper-resistant tablet platforms
• Contract development and manufacturing of controlled products

A manufacturer with an approved facility, established pseudoephedrine distribution controls, and experience with modified-release tablets has an advantage over a company entering the category for the first time.

The most attractive commercial model is likely a focused generic launch supported by a contract manufacturing agreement rather than a large branded relaunch. A relaunch would require investment in physician promotion, retail access, and patient awareness while competing with better-known pseudoephedrine combinations.

What generic launch scenarios are most plausible?

Scenario 1: Conventional ANDA launch

The applicant uses a standard hydrophilic matrix and conventional film coat. This offers the lowest manufacturing complexity but may face dissolution-development risk.

Scenario 2: Differentiated matrix formulation

The applicant uses a co-processed excipient or blended-polymer matrix to improve release reproducibility. This can support a stronger technical file but may increase formulation cost.

Scenario 3: Authorized-generic or licensed supply

The product is manufactured under a commercial agreement with the brand owner or an established licensee. This reduces patent and reference-product uncertainty but limits margin and strategic control.

Scenario 4: Combination-product repositioning

A company markets a comparable desloratadine-pseudoephedrine product under a new label or private-label arrangement. The opportunity depends on regulatory rights, trademark clearance, supply economics, and pharmacy demand.

Key Takeaways

• CLARINEX-D 12 HOUR contains desloratadine 2.5 mg and pseudoephedrine sulfate 120 mg in an extended-release tablet.
• Hypromellose is the central release-controlling excipient, while microcrystalline cellulose, dibasic calcium phosphate, povidone, colloidal silicon dioxide, and sodium starch glycolate support tablet manufacture and performance.
• The main generic barrier is formulation reproducibility, not active-ingredient novelty.
• Pseudoephedrine controls materially affect distribution, retailing, inventory, and compliance costs.
• Biosimilar competition is irrelevant because CLARINEX-D 12 HOUR is a small-molecule drug.
• The most attractive excipient opportunities involve controlled-release polymers, direct-compression platforms, content-uniformity systems, moisture control, and tamper resistance.
• Generic entry should be evaluated through current Orange Book listings, FDA exclusivity data, patent expiration information, and product-specific litigation records.
• A conventional ANDA or authorized-generic strategy is more commercially plausible than a high-cost branded relaunch.

FAQs About CLARINEX-D 12 HOUR Excipient and Commercial Strategy

What is the most important excipient in a generic CLARINEX-D 12 HOUR tablet?

Hypromellose is generally the most important because it controls pseudoephedrine release through a hydrated matrix. Its grade, viscosity, concentration, and compression behavior can materially change dissolution.

Can a generic manufacturer use different excipients from CLARINEX-D 12 HOUR?

Yes. FDA generic requirements generally permit different inactive ingredients if the product meets applicable pharmaceutical equivalence, bioequivalence, safety, quality, and labeling requirements.

Does CLARINEX-D 12 HOUR have biosimilar risk?

No. It is a small-molecule combination drug. Competition would arise through generic drug applications rather than biosimilar applications.

Why is pseudoephedrine a commercial barrier for generic manufacturers?

Pseudoephedrine is subject to federal and state sales, storage, recordkeeping, and distribution controls. These requirements increase operational costs and limit some retail and online channels.

What is the most defensible formulation design-around strategy?

A multilayer or multiparticulate system that separates rapid desloratadine availability from controlled pseudoephedrine release may provide a technically credible design-around, subject to bioequivalence, dissolution, stability, and patent review.

References

1. U.S. Food and Drug Administration. (2005). CLARINEX-D 12 HOUR extended release tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2012). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

4. U.S. Food and Drug Administration. (2017). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. FDA.

5. U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177.